JP2016520133A - キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 - Google Patents

キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 Download PDF

Info

Publication number
JP2016520133A
JP2016520133A JP2016517049A JP2016517049A JP2016520133A JP 2016520133 A JP2016520133 A JP 2016520133A JP 2016517049 A JP2016517049 A JP 2016517049A JP 2016517049 A JP2016517049 A JP 2016517049A JP 2016520133 A JP2016520133 A JP 2016520133A
Authority
JP
Japan
Prior art keywords
dosage form
febuxostat
release dosage
administration
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016517049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520133A5 (enExample
Inventor
ラノー グナワルダナ
ラノー グナワルダナ
ヴィジェイ グプテ
ヴィジェイ グプテ
ヒマンシュ ナイク
ヒマンシュ ナイク
マイケル メイヤー
マイケル メイヤー
完爾 小松
完爾 小松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of JP2016520133A publication Critical patent/JP2016520133A/ja
Publication of JP2016520133A5 publication Critical patent/JP2016520133A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016517049A 2013-05-31 2014-05-30 キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 Pending JP2016520133A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US61/829,759 2013-05-31
US201361839609P 2013-06-26 2013-06-26
US61/839,609 2013-06-26
PCT/US2014/040286 WO2014194226A2 (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019034081A Division JP2019108356A (ja) 2013-05-31 2019-02-27 キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物

Publications (2)

Publication Number Publication Date
JP2016520133A true JP2016520133A (ja) 2016-07-11
JP2016520133A5 JP2016520133A5 (enExample) 2017-07-06

Family

ID=50983231

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016517049A Pending JP2016520133A (ja) 2013-05-31 2014-05-30 キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
JP2019034081A Pending JP2019108356A (ja) 2013-05-31 2019-02-27 キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019034081A Pending JP2019108356A (ja) 2013-05-31 2019-02-27 キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物

Country Status (9)

Country Link
US (2) US20140357683A1 (enExample)
JP (2) JP2016520133A (enExample)
CN (1) CN105579037A (enExample)
CA (1) CA2913755A1 (enExample)
MX (1) MX2015016494A (enExample)
PH (1) PH12015502679A1 (enExample)
SG (2) SG11201509738RA (enExample)
TW (1) TW201536284A (enExample)
WO (1) WO2014194226A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018016623A (ja) * 2016-07-13 2018-02-01 日本ケミファ株式会社 ２−［３−シアノ−４−（２−メチルプロポキシ）フェニル］−４−メチルチアゾール−５−カルボン酸の口腔内崩壊錠
JPWO2020246528A1 (enExample) * 2019-06-04 2020-12-10
JP2024520138A (ja) * 2021-06-15 2024-05-21 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (zh) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 一种托匹司他纳米乳及其制备方法
EP3957629B1 (en) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Process for making deuterated hydroxy-benzbromarone and intermediates thereof
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
CN115252567A (zh) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 非布司他渗透泵缓释片及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) * 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
WO2007043457A1 (ja) * 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
WO2010113942A1 (ja) * 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
WO2011159745A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
ES2505690T3 (es) 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) * 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
WO2007043457A1 (ja) * 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
WO2010113942A1 (ja) * 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
WO2011159745A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
大野岩男 ほか: "通風を含む高尿酸血症患者を対象とした新規キサンチンオキシダーゼ阻害剤topiroxostat(FYX-510)の前期第Ｉ", 日本通風・核酸代謝学会総会プログラム・抄録集, vol. 44, JPN6018006630, 2011, pages 48, ISSN: 0003746394 *
山中寿: "痛風における尿酸コントロールの目標とコントロール剤の選択，使い方 Medical control of uric acid in pa", 日本臨牀, vol. 49, no. 5, JPN6018006627, 1991, pages 109 - 1093, ISSN: 0003904662 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018016623A (ja) * 2016-07-13 2018-02-01 日本ケミファ株式会社 ２−［３−シアノ−４−（２−メチルプロポキシ）フェニル］−４−メチルチアゾール−５−カルボン酸の口腔内崩壊錠
JP2022093470A (ja) * 2016-07-13 2022-06-23 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
JP7108384B2 (ja) 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
JP7361833B2 (ja) 2016-07-13 2023-10-16 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
JPWO2020246528A1 (enExample) * 2019-06-04 2020-12-10
WO2020246528A1 (ja) 2019-06-04 2020-12-10 日本ケミファ株式会社 痛風又は高尿酸血症の治療薬
KR20220016861A (ko) 2019-06-04 2022-02-10 닛뽕 케미파 가부시키가이샤 통풍 또는 고뇨산혈증의 치료약
JP2024520138A (ja) * 2021-06-15 2024-05-21 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
JP2024520150A (ja) * 2021-06-15 2024-05-21 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
JP7668386B2 (ja) 2021-06-15 2025-04-24 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物

Also Published As

Publication number Publication date
CA2913755A1 (en) 2014-12-04
SG10201709955PA (en) 2018-01-30
US20180311217A1 (en) 2018-11-01
WO2014194226A2 (en) 2014-12-04
US20140357683A1 (en) 2014-12-04
PH12015502679A1 (en) 2016-03-07
TW201536284A (zh) 2015-10-01
WO2014194226A3 (en) 2015-05-14
JP2019108356A (ja) 2019-07-04
MX2015016494A (es) 2016-11-18
SG11201509738RA (en) 2015-12-30
CN105579037A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
JP2019108356A (ja) キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
ZA200208204B (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with AT1-receptor antagonists.
KR20140022048A (ko) 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제
JP2017532376A (ja) 過度のフィブリン沈着及び／または血栓形成に関連する病理学的状態の治療または予防のための化合物及び組成物
US12121566B2 (en) Methods for treating gout
JP2022191405A (ja) 結節性痒疹を治療するための抗掻痒剤
Assaraf et al. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study
CN115003297A (zh) 使用伐达度司他的治疗方法
RU2706708C2 (ru) Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
US20150148388A1 (en) Chemical composition
US20160120885A1 (en) Fixed dose combination for pain relief without edema
EP4335438A1 (en) Combination therapy with vildagliptin and metformin
EP4360631A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN116887843A (zh) 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法
HK1224561A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
US20240100011A1 (en) Pediatric formulations of ferric citrate
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
US20190125727A1 (en) Fixed dose combination for pain relief without edema
CN111526875A (zh) 用于治疗骨关节炎疼痛的mPGES-1抑制剂
EP4426429A1 (en) Methods of treating patients having type 1 diabetes with eflornithine
US20080160081A1 (en) Alfuzosin formulations, methods of making, and methods of use
WO2018031577A1 (en) Fixed dose combination for pain relief without edema
HK40025703A (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160119

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181030